[go: up one dir, main page]

Saigal et al., 2013 - Google Patents

Evaluation of serotonin 5‐HT1A receptors in rodent models using [18F] mefway PET

Saigal et al., 2013

View PDF
Document ID
16333887441299419935
Author
Saigal N
Bajwa A
Faheem S
Coleman R
Pandey S
Constantinescu C
Fong V
Mukherjee J
Publication year
Publication venue
Synapse

External Links

Snippet

ABSTRACT Introduction Serotonin 5‐HT1A receptors have been investigated in various CNS disorders, including epilepsy, mood disorders, and neurodegeneration.[18F] Mefway (N‐{2‐[4‐(2′‐methoxyphenyl) piperazinyl] ethyl}‐N‐(2‐pyridyl)‐N‐(cis/trans− 4′‐[18F] …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/02—Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computerised tomographs
    • A61B6/037—Emission tomography

Similar Documents

Publication Publication Date Title
Saigal et al. Evaluation of serotonin 5‐HT1A receptors in rodent models using [18F] mefway PET
Virdee et al. Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders
Boschi et al. Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS (AHX)-HBED-CC PSMA ligand
Eisenstein et al. Characterization of extrastriatal D2 in vivo specific binding of [18F](N‐methyl) benperidol using PET
Hjørnevik et al. Biodistribution and radiation dosimetry of 18F-FTC-146 in humans
Wu et al. A novel PET marker for in vivo quantification of myelination
Lesche et al. Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer
Mukherjee et al. Human brain imaging of nicotinic acetylcholine α4β2* receptors using [18 F] N ifene: selectivity, functional activity, toxicity, aging effects, gender effects, and extrathalamic pathways
McParland et al. The clinical safety, biodistribution and internal radiation dosimetry of [18F] fluciclovine in healthy adult volunteers
Hu et al. Current status and future perspective of radiopharmaceuticals in China
Hohberg et al. Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer
Mukherjee et al. Comparative assessment of 18F‐Mefway as a serotonin 5‐HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humans
Devous Single-photon emission computed tomography in neurotherapeutics
Luoto et al. 11C-ORM-13070, a novel PET ligand for brain α2C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men
Wooten et al. In vivo kinetics of [F‐18] MEFWAY: A comparison with [C‐11] WAY100635 and [F‐18] MPPF in the nonhuman primate
AU2014337102B2 (en) Imaging histone deacetylases with a radiotracer using positron emission tomography
Hillmer et al. Specific α4β2 nicotinic acetylcholine receptor binding of [F‐18] nifene in the rhesus monkey
Chang et al. GMP-compliant fully automated radiosynthesis of [18F] FEPPA for PET/MRI imaging of regional brain TSPO expression
Joshi et al. Characterization of the novel GlyT1 PET tracer [18F] MK‐6577 in humans
Kimura et al. [11C] TASP457, a novel PET ligand for histamine H3 receptors in human brain
Mori et al. Development of 2-(2-(3-(4-([18F] Fluoromethoxy-d 2) phenyl)-7-methyl-4-oxo-3, 4-dihydroquinazolin-2-yl) ethyl)-4-isopropoxyisoindoline-1, 3-dione for Positron-Emission-Tomography Imaging of Phosphodiesterase 10A in the Brain
Hocke et al. Biodistribution studies of two 18F-labeled pyridinylphenyl amides as subtype selective radioligands for the dopamine D3 receptor
Saba et al. [11C] LBT‐999: A suitable radioligand for investigation of extra‐striatal dopamine transporter with PET
Giboureau et al. Ex vivo and in vivo evaluation of (2R, 3R)‐5‐[18F]‐fluoroethoxy‐and fluoropropoxy‐benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter
Sakata et al. Assessment of safety, efficacy, and dosimetry of a novel 18-kDa translocator protein ligand,[11C] CB184, in healthy human volunteers